Advertisement

Adjuvant Therapy of Colorectal Cancer in Older People

  • Aimery de GramontEmail author
  • Leila Bengrine-Lefevre
  • May Mabro
  • Elisabeth Carola
Chapter

Abstract

Colorectal cancer (CRC) is the fourth cause of cancer deaths. More than one-third of colon cancers are stage III at presentation; their 5-year relative survival is 69 %.

Among the high-incidence cancers, CRC has the highest median age at presentation. Thus, the administration of adjuvant therapy after curative surgery for elderly patients remains a burning question in daily practice.

In the adjuvant setting, while there is an advantage in relapse-free survival with adjuvant therapy, there is no evidence-based survival benefit for adjuvant therapy due to confounding non-cancer-related deaths. However, with an optimal and careful management of relapses or second cancers, a survival benefit with adjuvant therapy is possible in some elderly patients. The use of a comprehensive geriatric assessment is strongly recommended to evaluate chemotherapy appropriateness. Elderly patients with good physical condition are able to receive combination therapy in a similar fashion to younger patients.

Keywords

Colorectal cancer Elderly Stage III Adjuvant chemotherapy Fluoropyrimidines Oxaliplatin Older patients Recurrence Survival 

References

  1. 1.
    UN Data. http://globocan.iarc.fr/summary_table_pop.asp. Accessed on December 4, 2012
  2. 2.
  3. 3.
    André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343–51.PubMedCrossRefGoogle Scholar
  4. 4.
    Kuebler JP, Wieand HS, O’Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol. 2007;25:2198–204.PubMedCrossRefGoogle Scholar
  5. 5.
    American Joint Committee on Cancer. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.Google Scholar
  6. 6.
    Chou JF, Row D, Gonen M, et al. Clinical and pathologic factors that predict lymph node yield from surgical specimens in colorectal cancer: a population-based study. Cancer. 2010;116:2560–70.PubMedCrossRefGoogle Scholar
  7. 7.
    Lee SJ, Lindquist K, Segal MR, et al. Development and validation of a prognostic index for 4-year mortality in older adults. JAMA. 2006;295:801–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Aparicio T, Girard L, Bouarioua N, et al. A mini geriatric assessment helps treatment decision in elderly patients with digestive cancer. A pilot study. Crit Rev Oncol Hematol. 2011;77:63–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Artaud F, Bellera C, Rainfray M, et al. Performance evaluation of screening tools in onco-geriatrics in a national ONCODAGE multicenter study from the national. Bull Cancer. 2011;98:S69–70.Google Scholar
  10. 10.
    Overcash JA, Beckstead J, Extermann M, et al. The abbreviated comprehensive geriatric assessment (aCGA): a retrospective analysis. Crit Rev Oncol Hematol. 2005;54:129–36.PubMedCrossRefGoogle Scholar
  11. 11.
    Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56:M146–56.PubMedCrossRefGoogle Scholar
  12. 12.
    Retornaz F, Monette J, Batist G, et al. Usefulness of frailty markers in the assessment of the health and functional status of older cancer patients referred for chemotherapy: a pilot study. J Gerontol A Biol Sci Med Sci. 2008;63:518–22.PubMedCrossRefGoogle Scholar
  13. 13.
    McCorkle R, Strumpf NE, Nuamah IF, et al. A specialized home care intervention improves survival among older post-surgical cancer patients. J Am Geriatr Soc. 2000;48:1707–13.PubMedGoogle Scholar
  14. 14.
    Blanc-Bisson C, Fonck M, Rainfray M, et al. Undernutrition in elderly patients with cancer: target for diagnosis and intervention. Crit Rev Oncol Hematol. 2008;67:243–54.PubMedCrossRefGoogle Scholar
  15. 15.
    Extermann M, Meyer J, McGinnis M, et al. A comprehensive geriatric intervention detects multiple problems in older breast cancer patients. Crit Rev Oncol Hematol. 2004;49:69–75.PubMedCrossRefGoogle Scholar
  16. 16.
    Girre V, Falcou MC, Gisselbrecht M, et al. Does a geriatric oncology consultation modify the cancer treatment plan for elderly patients? J Gerontol A Biol Sci Med Sci. 2008;63:724–30.PubMedCrossRefGoogle Scholar
  17. 17.
    Balducci L, Extermann M. Management of cancer in the older person: a practical approach. Oncologist. 2000;5:224–37.PubMedCrossRefGoogle Scholar
  18. 18.
    Sanoff HK, Bleiberg H, Goldberg RM. Managing older patients with colorectal cancer. J Clin Oncol. 2007;25:1891–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Extermann M, Boler I, Reich RR, et al. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer. 2012;118:3377–86.PubMedCrossRefGoogle Scholar
  20. 20.
    Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999;341:2061–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Kemeny MM, Peterson BL, Kornblith AB, et al. Barriers to clinical trial participation by older women with breast cancer. J Clin Oncol. 2003;21:2268–75.PubMedCrossRefGoogle Scholar
  22. 22.
    Mahoney T, Kuo YH, Topilow A, et al. Stage III colon cancers: why adjuvant chemotherapy is not offered to elderly patients. Arch Surg. 2000;135:182–5.PubMedCrossRefGoogle Scholar
  23. 23.
    Extermann M, Albrand G, Chen H, et al. Are older French patients as willing as older American patients to undertake chemotherapy? J Clin Oncol. 2003;21:3214–9.PubMedCrossRefGoogle Scholar
  24. 24.
  25. 25.
    Sargent DJ, Patiyil S, Yothers G, et al. End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. J Clin Oncol. 2007;25:4569–74.PubMedCrossRefGoogle Scholar
  26. 26.
    Saltz LB, Niedzwiecki D, Hollis D, et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol. 2007;25:3456–61.PubMedCrossRefGoogle Scholar
  27. 27.
    Van Cutsem E, Labianca R, Bodoky G, et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol. 2009;27:3117–25.PubMedCrossRefGoogle Scholar
  28. 28.
    Lembersky BC, Wieand HS, Petrelli NJ, et al. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol. 2006;24:2059–64.PubMedCrossRefGoogle Scholar
  29. 29.
    Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005;352:2696–704.PubMedCrossRefGoogle Scholar
  30. 30.
    André T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27:3109–16.PubMedCrossRefGoogle Scholar
  31. 31.
    Haller DG, Tabernero J, Maroun J, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 2011;29:1465–71.PubMedCrossRefGoogle Scholar
  32. 32.
    Tournigand C, de Gramont A. Chemotherapy: is adjuvant chemotherapy an option for stage II colon cancer? Nat Rev Clin Oncol. 2011;8:574–6.PubMedCrossRefGoogle Scholar
  33. 33.
    Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990;322:352–8.PubMedCrossRefGoogle Scholar
  34. 34.
    Wolmark N, Rockette H, Mamounas E, et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes’ B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol. 1999;17:3553–9.PubMedGoogle Scholar
  35. 35.
    André T, Quinaux E, Louvet C, et al. Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1. J Clin Oncol. 2007;25:3732–8.PubMedCrossRefGoogle Scholar
  36. 36.
    Gray R, Barnwell J, McConkey C, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370:2020–9.PubMedCrossRefGoogle Scholar
  37. 37.
    Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010;28:3219–26.PubMedCrossRefGoogle Scholar
  38. 38.
    André T. A multinational, randomized phase III study of bevacizumab with FOLFOX4 or XELOX versus FOLFOX4 alone as adjuvant treatment for colon cancer: subgroup analyses from the AVANT trial. J Clin Oncol. 2011;29:223s.CrossRefGoogle Scholar
  39. 39.
    Alberts SR, Sargent DJ, Smyrrk TC, et al. Adjuvant mFOLFOX6 with or without cetuximab in KRAS wild-type patients with resected stage III colon cancer: results from NCCTG intergroup phase III trial NO147. J Clin Oncol. 2010;28:959s.CrossRefGoogle Scholar
  40. 40.
    Allegra CJ, Yothers G, O’Connell MJ, et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol. 2011;29:11–6.PubMedCrossRefGoogle Scholar
  41. 41.
    Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med. 2001;345:1091–7.PubMedCrossRefGoogle Scholar
  42. 42.
    Iwashyna TJ, Lamont EB. Effectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with stage III colon cancer. J Clin Oncol. 2002;20:3992–8.PubMedCrossRefGoogle Scholar
  43. 43.
    Kahn KL, Adams JL, Weeks JC, et al. Adjuvant chemotherapy use and adverse events among older patients with stage III colon cancer. JAMA. 2010;303:1037–45.PubMedCrossRefGoogle Scholar
  44. 44.
    Jackson McCleary NA, Meyerhardt J, Green E, et al. Impact of older age on the efficacy of newer adjuvant therapies in >12500 patients with stage II/III colon cancer: findings from the ACCENT database. J Clin Oncol. 2009;27(15S):4010.Google Scholar
  45. 45.
    Tournigand C, André T, Bonnetain F, et al. Adjuvant therapy with 5-fluorouracil and oxaliplatin in stage II and elderly patients (aged between 70 and 75 years) with colon cancer: subgroup analyses of the MOSAIC Trial. J Clin Oncol. 2012;30(27):3353–60.PubMedCrossRefGoogle Scholar
  46. 46.
    Haller D, Cassidy J, Tabernero J, et al. Phase III trial of capecitabine + oxaliplatin vs bolus 5-FU/LV in stage III colon cancer (NO16968): impact of age on DFS and OS. ASCO GI, San Fransico, 2010Google Scholar
  47. 47.
    Yothers G, O’Connell MJ, Allegra CJ, et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol. 2011;29:3768–74.PubMedCrossRefGoogle Scholar
  48. 48.
    Haller DG, O’Connell M, Cartwright TH, et al. Impact of age and medical comorbidity (MC) on adjuvant treatment outcomes for stage III colon cancer (CC): a pooled analysis of individual patient data from four randomized controlled trials. J Clin Oncol. 2012;30(suppl; abstr 3522).Google Scholar
  49. 49.
    Saliba D, Elliott M, Rubenstein LZ, et al. The Vulnerable Elders Survey: a tool for identifying vulnerable older people in the community. J Am Geriatr Soc. 2001;49:1691–9.PubMedCrossRefGoogle Scholar
  50. 50.
    Luciani A, Ascione G, Bertuzzi C, et al. Detecting disabilities in older patients with cancer: comparison between comprehensive geriatric assessment and vulnerable elders survey-13. J Clin Oncol. 2010;28:2046–50.PubMedCrossRefGoogle Scholar
  51. 51.
    Goldberg RM, Tabah-Fisch I, Bleiberg H, et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol. 2006;24:4085–91.PubMedCrossRefGoogle Scholar
  52. 52.
    Schmoll HJ, Cartwright T, Tabernero J, et al. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol. 2007;25:102–9.PubMedCrossRefGoogle Scholar
  53. 53.
    Feliu J, Escudero P, Llosa F, et al. Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an oncopaz cooperative group study. J Clin Oncol. 2005;23:3104–11.PubMedCrossRefGoogle Scholar
  54. 54.
    Feliu J, Salud A, Escudero P, et al. XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. Br J Cancer. 2006;94:969–75.PubMedCrossRefGoogle Scholar
  55. 55.
    de Gramont A, Chibaudel B, Bachet JB, et al. From chemotherapy to targeted therapy in adjuvant treatment for stage III colon cancer. Semin Oncol. 2011;38:521–32.PubMedCrossRefGoogle Scholar
  56. 56.
    Buyse M, Sargent DJ, Grothey A, et al. Biomarkers and surrogate end points – the challenge of statistical validation. Nat Rev Clin Oncol. 2010;7:309–17.PubMedCrossRefGoogle Scholar
  57. 57.
    Gray RG, Quirke P, Handley K, et al. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J Clin Oncol. 2011;29:4611–9.PubMedCrossRefGoogle Scholar
  58. 58.
    Kennedy RD, Bylesjo M, Kerr P, et al. Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue. J Clin Oncol. 2011;29:4620–6.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2013

Authors and Affiliations

  • Aimery de Gramont
    • 1
    • 2
    Email author
  • Leila Bengrine-Lefevre
    • 3
  • May Mabro
    • 4
  • Elisabeth Carola
    • 5
  1. 1.Department of Medical OncologyGERCORParisFrance
  2. 2.Department of Medical OncologyHopital Saint-AntoineParisFrance
  3. 3.Oncology DepartmentSaint Antoine HospitalParisFrance
  4. 4.OncologieHopital FochSuresnesFrance
  5. 5.Oncologie MédicaleGHPSOSenlisFrance

Personalised recommendations